A recent study suggests that people who come off new weight-loss injections like semaglutide or tirzepatide can put back on shed pounds far faster than those who end traditional lifestyle plans.
Published data in a major medical journal shows that while obese people often shed substantial amounts of their body weight while on the medication, the weight comes back at an estimated rate of 0.8 kg per month after stopping.
"Individuals buying such medications need to be cognizant of the danger of rapid rebound weight gain when the therapy ends," stated expert Dr. Susan Jebb.
This pace of recovery means a reversion to pre-treatment weight within about a year and a half.
Analyzing Approaches
The research, which looked at 37 of studies involving thousands of participants, compared the effects of GLP-1 agonists with other pills.
The team point out that people who lose weight through diet and exercise generally see a more gradual creep back—approximately 0.1 kg a month—post-intervention.
Understanding the Rapid Regain
Doctors suggest the mode of action of the jabs accounts for the amplified rebound.
These medications imitate a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 concentrations far above than normal may cause the body to produce less of its own natural GLP-1, and could reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' results in appetite is no longer kept in check, making overeating much more probable."
A Chronic Condition?
Health authorities suggest the jabs for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications.
A number of clinicians say that, due to the likelihood of weight regain, the therapy should be considered life-long.
This view is echoed by pharmaceutical companies, who state that the results "highlight the long-term nature of obesity," comparing it to managing conditions like hypertension.
User Testimonies
Individuals who have discontinued the medication explain a intense return of cravings.
"It felt as if a trigger flipping and you become starving," said an individual.
The struggle is compounded if individuals have not established lasting dietary or behavioural modifications during therapy.
Widespread Adoption
Survey data show that millions of adults in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Use is more common among females than men.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
Ultimately, clinicians stress that while these medications are powerful tools for weight loss, they are not a permanent solution and lasting health benefits relies on ongoing behavioural changes.
